MX342474B - Poblaciones celulares con actividad inmunoreguladora, método de aislamiento y usos. - Google Patents

Poblaciones celulares con actividad inmunoreguladora, método de aislamiento y usos.

Info

Publication number
MX342474B
MX342474B MX2013012947A MX2013012947A MX342474B MX 342474 B MX342474 B MX 342474B MX 2013012947 A MX2013012947 A MX 2013012947A MX 2013012947 A MX2013012947 A MX 2013012947A MX 342474 B MX342474 B MX 342474B
Authority
MX
Mexico
Prior art keywords
cells
isolation
express
cell populations
immunoregulatory activity
Prior art date
Application number
MX2013012947A
Other languages
English (en)
Spanish (es)
Inventor
Angel Gonzalez De La Peña Manuel
Büscher Dirk
Delgado Mora Mario
Original Assignee
Cellerix Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37708240&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX342474(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cellerix Sl filed Critical Cellerix Sl
Publication of MX342474B publication Critical patent/MX342474B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2013012947A 2005-09-23 2006-09-22 Poblaciones celulares con actividad inmunoreguladora, método de aislamiento y usos. MX342474B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05077186 2005-09-23
PCT/EP2006/009244 WO2007039150A2 (en) 2005-09-23 2006-09-22 Cell populations having immunoregulatory activity, method for isolation and uses

Publications (1)

Publication Number Publication Date
MX342474B true MX342474B (es) 2016-09-30

Family

ID=37708240

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013012947A MX342474B (es) 2005-09-23 2006-09-22 Poblaciones celulares con actividad inmunoreguladora, método de aislamiento y usos.

Country Status (19)

Country Link
US (5) US20090130067A1 (https=)
EP (4) EP2340847B1 (https=)
JP (2) JP5925408B2 (https=)
KR (2) KR101536239B1 (https=)
CN (2) CN101313062A (https=)
AU (1) AU2006299144A1 (https=)
CA (2) CA2953782C (https=)
CY (1) CY1117972T1 (https=)
DK (1) DK1926813T4 (https=)
ES (2) ES2589311T5 (https=)
HU (1) HUE030503T2 (https=)
IL (3) IL190363A0 (https=)
LT (1) LT1926813T (https=)
MX (1) MX342474B (https=)
PL (1) PL1926813T5 (https=)
PT (1) PT1926813T (https=)
SG (3) SG165418A1 (https=)
SI (1) SI1926813T2 (https=)
WO (1) WO2007039150A2 (https=)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060045872A1 (en) 2004-08-25 2006-03-02 Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco Use of adipose tissue-derived stromal stem cells in treating fistula
KR101536239B1 (ko) 2005-09-23 2015-07-13 셀레릭스, 에스.엘. 면역조절활성을 갖는 세포 개체군, 분리 방법 및 용도
WO2007070660A2 (en) 2005-12-13 2007-06-21 President And Fellows Of Harvard College Scaffolds for cell transplantation
US7989173B2 (en) 2006-12-27 2011-08-02 The Johns Hopkins University Detection and diagnosis of inflammatory disorders
CN102006891B (zh) 2008-02-13 2017-04-26 哈佛学院董事会 连续的细胞程序化装置
JP2011515470A (ja) 2008-03-28 2011-05-19 ステムサイト インコーポレーテッド 臍帯血細胞を用いた脳損傷の処置
EP3320912B1 (en) * 2008-04-17 2021-03-31 IO BIOTECH ApS Indoleamine 2, 3-dioxygenase based immunotherapy
GB0814249D0 (en) * 2008-08-04 2008-09-10 Cellerix Sa Uses of mesenchymal stem cells
AU2009201915C1 (en) 2008-08-22 2015-02-26 Regeneus Ltd Therapeutic methods
EP2204442A1 (en) * 2008-10-01 2010-07-07 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Method of enriching stem cells in culture
GB0820397D0 (en) 2008-11-07 2008-12-17 Cellerix Sa Cells, nucleic acid constructs, cells comprising said constructs and methods utilizing said cells in the treatment of diseases
EP3150703A1 (en) 2009-07-09 2017-04-05 TiGenix, S.A.U. Cells for use in a method for treating inflammatory and/or immune disorders
AU2010278702C1 (en) 2009-07-31 2016-07-14 Forsyth Dental Infirmary For Children Programming of cells for tolerogenic therapies
CA2772204A1 (en) 2009-08-31 2011-03-03 Amplimmune, Inc. Methods and compositions for the inhibition of transplant rejection
GB0918615D0 (en) 2009-10-23 2009-12-09 Cellerix Sa Cell populations having immunoregulatory activity, methods for the preparation and uses thereof
US10130736B1 (en) 2010-05-14 2018-11-20 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US9352003B1 (en) 2010-05-14 2016-05-31 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US8883210B1 (en) 2010-05-14 2014-11-11 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
CN107648668B (zh) 2010-10-06 2021-06-18 哈佛学院董事会 用于基于材料的细胞疗法的可注射的成孔水凝胶
US20140154274A1 (en) 2011-01-12 2014-06-05 Tigenix Nv Methods and compositions for use in intralymphatic cellular therapies
KR20140016933A (ko) * 2011-03-11 2014-02-10 타이제닉스, 에스.에이.유. 면역조절 활성을 갖는 세포군, 분리방법 및 용도들
ES2661454T3 (es) * 2011-04-25 2018-04-02 University Of Southern California Composiciones para la regeneración mejorada de tejidos por supresión de interferón-gamma y factor de necrosis tumoral-alfa
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
US8834928B1 (en) 2011-05-16 2014-09-16 Musculoskeletal Transplant Foundation Tissue-derived tissugenic implants, and methods of fabricating and using same
US20140348808A1 (en) 2011-05-19 2014-11-27 Olga De La Rosa Cell populations having immunoregulatory activity, methods for the preparation and uses thereof
DK2838515T3 (da) 2012-04-16 2020-02-24 Harvard College Mesoporøse siliciumdioxidsammensætninger til modulering af immunresponser
EP3013943B1 (en) * 2013-06-25 2019-04-10 TiGenix, S.A.U. Cell populations having immunoregulatory activity, methods for the preparation and uses thereof
US20150037436A1 (en) 2013-07-30 2015-02-05 Musculoskeletal Transplant Foundation Acellular soft tissue-derived matrices and methods for preparing same
CA2930665A1 (en) 2013-11-18 2015-05-21 Rubius Therapeutics, Inc. Synthetic membrane-receiver complexes
MA39819A (fr) * 2014-04-01 2017-02-08 Rubius Therapeutics Inc Méthodes et compositions d'immunomodulation
EP3137105A4 (en) 2014-04-30 2017-12-27 President and Fellows of Harvard College Combination vaccine devices and methods of killing cancer cells
WO2016001845A1 (en) 2014-06-30 2016-01-07 Tigenix S.A.U. Mesenchymal stromal cells for treating rheumatoid arthritis
JP6722599B2 (ja) 2014-06-30 2020-07-15 ティジェニクス エス．エー．ユー． 全身性炎症反応症候群の治療のための間葉系間質細胞
JP2016017068A (ja) * 2014-07-10 2016-02-01 国立大学法人金沢大学 脂肪組織由来間質細胞群を含む消化管炎症治療剤
KR101675521B1 (ko) * 2014-07-11 2016-11-17 대한민국 인돌아민 2,3-디옥시게나아제를 이용하여 인터페론-감마의 발현을 조절하는 방법
US11786457B2 (en) 2015-01-30 2023-10-17 President And Fellows Of Harvard College Peritumoral and intratumoral materials for cancer therapy
WO2016164705A1 (en) 2015-04-10 2016-10-13 Omar Abdel-Rahman Ali Immune cell trapping devices and methods for making and using the same
CA2986702C (en) 2015-05-21 2023-04-04 David Wang Modified demineralized cortical bone fibers
US10912864B2 (en) 2015-07-24 2021-02-09 Musculoskeletal Transplant Foundation Acellular soft tissue-derived matrices and methods for preparing same
US11052175B2 (en) 2015-08-19 2021-07-06 Musculoskeletal Transplant Foundation Cartilage-derived implants and methods of making and using same
US11752238B2 (en) 2016-02-06 2023-09-12 President And Fellows Of Harvard College Recapitulating the hematopoietic niche to reconstitute immunity
EP3419635B1 (en) 2016-02-22 2022-01-05 Centauri Biotech, S.L. Pharmaceutical or veterinary cell compositions comprising mesenchymal stromal cells (mscs) and dimethyl sulfoxide (dmso)
GB201604304D0 (en) 2016-03-14 2016-04-27 Tigenix S A U Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease
CN109789092A (zh) 2016-07-13 2019-05-21 哈佛学院院长等 抗原呈递细胞模拟支架及其制备和使用方法
IL264557B2 (en) 2016-08-02 2024-01-01 Harvard College Biological agents for regulating immune responses
EP4417210A1 (en) 2017-03-15 2024-08-21 Orca Biosystems, Inc. Compositions and methods for hematopoietic stem cell transplants
EP3765600A1 (en) 2018-03-13 2021-01-20 Oxacell AG Cell products with improved stability and uses thereof
CA3103043A1 (en) 2018-06-15 2019-12-19 Luis Marinas Pardo Pharmaceutical composition for dermatology and uses thereof
WO2020061129A1 (en) 2018-09-19 2020-03-26 President And Fellows Of Harvard College Compositions and methods for labeling and modulation of cells in vitro and in vivo
AU2019447274A1 (en) * 2019-05-21 2021-12-09 Emo Biomedicine Corp. Use of mesenchymal stem cells in treating immune-related diseases
WO2021061837A1 (en) 2019-09-23 2021-04-01 President And Fellows Of Harvard College Biomaterial-based antigen free vaccine and the use thereof
EP4096720A2 (en) * 2020-01-30 2022-12-07 ModernaTX, Inc. Mrnas encoding metabolic reprogramming polypeptides and uses thereof
KR102438419B1 (ko) * 2021-12-01 2022-09-01 메디포스트(주) Cd47 과발현 중간엽 줄기세포를 포함하는 폐 질환 예방 또는 치료용 조성물

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145770A (en) 1990-06-04 1992-09-08 Biosurface Technology, Inc. Cryopreservation of cultured epithelial sheets
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5733542A (en) * 1990-11-16 1998-03-31 Haynesworth; Stephen E. Enhancing bone marrow engraftment using MSCS
US6010696A (en) 1990-11-16 2000-01-04 Osiris Therapeutics, Inc. Enhancing hematopoietic progenitor cell engraftment using mesenchymal stem cells
US5709854A (en) 1993-04-30 1998-01-20 Massachusetts Institute Of Technology Tissue formation by injecting a cell-polymeric solution that gels in vivo
US6174333B1 (en) 1994-06-06 2001-01-16 Osiris Therapeutics, Inc. Biomatrix for soft tissue regeneration using mesenchymal stem cells
CA2192103C (en) 1994-06-06 2002-02-05 Arnold I. Caplan Biomatrix for tissue regeneration
CN1166773C (zh) * 1997-12-02 2004-09-15 泽恩比奥公司 分离的人脂肪组织衍生的基质细胞
US6451840B1 (en) 1997-12-05 2002-09-17 Medical College Of Georgia Research Institute, Inc. Regulation of T cell-mediated immunity by tryptophan
AU748443B2 (en) 1998-02-04 2002-06-06 General Hospital Corporation, The Costimulatory blockade and mixed chimerism in transplantation
US6368636B1 (en) * 1998-03-18 2002-04-09 Osiris Therapeutics, Inc. Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
US9585916B2 (en) 1999-03-26 2017-03-07 Northern Therapeutics Inc. Cell based therapy for the pulmonary system
PT1066060E (pt) 1998-04-03 2003-12-31 Osiris Therapeutics Inc Celulas estaminais mesenquimais como imunossupressores
US6777231B1 (en) 1999-03-10 2004-08-17 The Regents Of The University Of California Adipose-derived stem cells and lattices
US20030082152A1 (en) 1999-03-10 2003-05-01 Hedrick Marc H. Adipose-derived stem cells and lattices
KR100979664B1 (ko) 1999-03-10 2010-09-02 유니버시티 오브 피츠버그 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 지방 유래 간세포 및 격자
US20050153442A1 (en) 1999-03-10 2005-07-14 Adam Katz Adipose-derived stem cells and lattices
US7670628B2 (en) 1999-07-07 2010-03-02 Angioblast Systems, Inc. Mesenchymal precursor cell
US7078232B2 (en) 1999-08-19 2006-07-18 Artecel, Inc. Adipose tissue-derived adult stem or stromal cells for the repair of articular cartilage fractures and uses thereof
US6555374B1 (en) 1999-08-19 2003-04-29 Artecel Sciences, Inc. Multiple mesodermal lineage differentiation potentials for adipose tissue-derived stromal cells and uses thereof
CA2392615A1 (en) 1999-12-06 2001-06-07 The General Hospital Corporation Pancreatic stem cells and their use in transplantation
US20020155096A1 (en) 2001-02-23 2002-10-24 Chancellor Michael B. Rapid preparation of stem cell matrices for use in tissue and organ treatment and repair
EP1241249A1 (en) * 2001-03-12 2002-09-18 Gerold Schuler CD4+CD25+regulatory T cells from human blood
US20030054331A1 (en) 2001-09-14 2003-03-20 Stemsource, Inc. Preservation of non embryonic cells from non hematopoietic tissues
JP2005508393A (ja) * 2001-11-09 2005-03-31 アーテセル・サイエンシズ・インコーポレーテツド 胚および成人幹細胞をサポートするための間質細胞の使用の方法および組成物
US7771716B2 (en) 2001-12-07 2010-08-10 Cytori Therapeutics, Inc. Methods of using regenerative cells in the treatment of musculoskeletal disorders
EP1455813B1 (en) * 2001-12-18 2015-07-15 mondoBIOTECH AG Interferon gamma in combination with a diagnostic array for use in the improved treatment of idiopathic pulmonary fibrosis
US7282222B2 (en) 2002-03-15 2007-10-16 The United States Of America As Represented By The Department Of Veterans Affairs Methods and compositions for directing cells to target organs
DK1513877T3 (da) 2002-06-14 2008-06-02 Cartela Ab Markör for stamceller og dens anvendelse
US20040204458A1 (en) * 2002-08-16 2004-10-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of Lck inhibitors for treatment of immunologic diseases
US20040101959A1 (en) 2002-11-21 2004-05-27 Olga Marko Treatment of tissue with undifferentiated mesenchymal cells
US7494812B2 (en) * 2003-04-01 2009-02-24 University Of Southern California Generation of human regulatory T cells by bacterial toxins for the treatment of inflammatory disorders
EP1608411B1 (en) 2003-04-01 2010-09-29 United States Government as represented by the Department of Veteran's Affaires Stem-cell, precursor cell, or target cell-based treatment of multi-organ failure.
ES2265199B1 (es) 2003-06-12 2008-02-01 Cellerix, S.L. Celulas madre adultas multipotentes procedentes de condrocitos desdiferenciados y sus aplicaciones.
WO2005001080A2 (en) 2003-06-27 2005-01-06 Ethicon, Incorporated Postpartum-derived cells for use in treatment of disease of the heart and circulatory system
WO2005035738A1 (en) 2003-10-07 2005-04-21 Biomaster Inc. Cell differentiation of adipose-derived precursor cells
US9631176B2 (en) 2003-11-04 2017-04-25 Biomaster, Inc. Method for preparing stem cells from fat tissue
WO2005062857A2 (en) 2003-12-24 2005-07-14 The Trustees Of Columbia University In The City Of New York Creation of a biological atrioventricular bypass to compensate for atrioventricular block
AU2005206746B2 (en) * 2004-01-08 2008-08-28 Regents Of The University Of California Regulatory t cells suppress autoimmunity
EP3461884B1 (en) * 2004-03-22 2025-05-28 Mesoblast International Sàrl Mesenchymal stem cells and uses therefor
US20080095749A1 (en) 2004-03-22 2008-04-24 Sudeepta Aggarwal Mesenchymal stem cells and uses therefor
RU2252252C1 (ru) 2004-04-09 2005-05-20 Тепляшин Александр Сергеевич Способ выделения мезенхимальных стволовых клеток
ES2264862B8 (es) 2004-08-25 2017-01-20 Cellerix, S.L. Biomaterial para sutura.
US20060045872A1 (en) 2004-08-25 2006-03-02 Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco Use of adipose tissue-derived stromal stem cells in treating fistula
ES2313805B1 (es) 2004-10-04 2009-12-23 Cellerix, S.L. Identificacion y aislamiento de celulas multipotentes de tejido mesenquimal no osteocondral.
US7732126B2 (en) 2004-09-03 2010-06-08 University Of Maryland, Baltimore Integrin CD18 is a novel stromal stem cell marker and functions to promote osteogenesis
WO2006110582A1 (en) 2005-04-08 2006-10-19 Xcyte Therapies, Inc. Compositions and methods for the treatment of burns and sepsis
KR101536239B1 (ko) 2005-09-23 2015-07-13 셀레릭스, 에스.엘. 면역조절활성을 갖는 세포 개체군, 분리 방법 및 용도
EP1795588A1 (en) 2005-12-07 2007-06-13 Cellerix, S.L. Use of adipose tissue derived mesenchymal stem cells for the treatment of graft versus host disease
WO2008036374A2 (en) 2006-09-21 2008-03-27 Medistem Laboratories, Inc. Allogeneic stem cell transplants in non-conditioned recipients
EP2191835A4 (en) 2007-09-07 2011-12-14 Japan Chem Res THERAPEUTIC AND PROPHYLACTIC AGENTS FOR ARTHRITIS
MX2010003019A (es) 2007-09-19 2010-04-30 Pluristem Ltd Celulas adherentes de los tejidos adiposo y de placenta y uso de las mismas en la terapia.
DK2205721T3 (en) 2007-10-17 2016-10-24 Txcell TR1 cells mesenchymal stem cells and uses thereof
GB0814249D0 (en) 2008-08-04 2008-09-10 Cellerix Sa Uses of mesenchymal stem cells
ES2345867B1 (es) 2009-04-03 2011-07-28 Fundacion Instituto Mediterraneo Para La Biotecnologia Y La Investigacion Sanitaria (Imabis) Celulas madre multipotentes derivadas de estroma de mesenterio.
EP3150703A1 (en) 2009-07-09 2017-04-05 TiGenix, S.A.U. Cells for use in a method for treating inflammatory and/or immune disorders
US20140154274A1 (en) 2011-01-12 2014-06-05 Tigenix Nv Methods and compositions for use in intralymphatic cellular therapies
KR20140016933A (ko) 2011-03-11 2014-02-10 타이제닉스, 에스.에이.유. 면역조절 활성을 갖는 세포군, 분리방법 및 용도들
US20140134140A1 (en) 2012-11-09 2014-05-15 Case Western Reserve University Mesenchymal stem cell compositions for the treatment of microbial infections
US10660920B2 (en) 2013-03-15 2020-05-26 Tigenix Nv Lymphocyte biomarkers for determining the clinical response to cell therapy
EP3013943B1 (en) 2013-06-25 2019-04-10 TiGenix, S.A.U. Cell populations having immunoregulatory activity, methods for the preparation and uses thereof

Also Published As

Publication number Publication date
SG10202001007TA (en) 2020-03-30
SG10201400793RA (en) 2014-08-28
IL246494B (en) 2021-09-30
SI1926813T1 (sl) 2016-10-28
IL228670A (en) 2017-06-29
PL1926813T5 (pl) 2019-11-29
CN107723274B (zh) 2021-05-07
SG165418A1 (en) 2010-10-28
ES2589311T3 (es) 2016-11-11
SI1926813T2 (sl) 2019-11-29
IL228670A0 (en) 2013-12-31
JP6089004B2 (ja) 2017-03-01
EP3184630B1 (en) 2019-07-17
JP2009508507A (ja) 2009-03-05
EP1926813A2 (en) 2008-06-04
JP5925408B2 (ja) 2016-05-25
EP1926813B2 (en) 2019-05-22
KR20080048555A (ko) 2008-06-02
CA2953782C (en) 2023-09-12
EP3184631B1 (en) 2020-08-12
CN101313062A (zh) 2008-11-26
DK1926813T4 (da) 2019-08-19
US20170296593A1 (en) 2017-10-19
ES2751692T3 (es) 2020-04-01
CA2623353A1 (en) 2007-04-12
HUE030503T2 (en) 2017-05-29
CA2623353C (en) 2017-02-21
ES2589311T5 (es) 2020-02-14
AU2006299144A1 (en) 2007-04-12
LT1926813T (lt) 2016-11-10
EP3184630A1 (en) 2017-06-28
EP3184631A1 (en) 2017-06-28
WO2007039150A2 (en) 2007-04-12
WO2007039150A3 (en) 2007-08-23
US20170296592A1 (en) 2017-10-19
KR101536239B1 (ko) 2015-07-13
PL1926813T3 (pl) 2017-01-31
PT1926813T (pt) 2016-09-06
US20150224146A1 (en) 2015-08-13
CN107723274A (zh) 2018-02-23
IL246494A0 (en) 2016-08-31
US20090130067A1 (en) 2009-05-21
EP2340847A2 (en) 2011-07-06
EP2340847B1 (en) 2025-11-05
US12186344B2 (en) 2025-01-07
CY1117972T1 (el) 2017-05-17
KR20140003631A (ko) 2014-01-09
EP1926813B1 (en) 2016-06-08
JP2014221045A (ja) 2014-11-27
US9943550B2 (en) 2018-04-17
IL190363A0 (en) 2011-08-01
EP2340847A3 (en) 2016-11-09
CA2953782A1 (en) 2007-04-12
US20220313742A1 (en) 2022-10-06
DK1926813T3 (en) 2016-09-19

Similar Documents

Publication Publication Date Title
MX342474B (es) Poblaciones celulares con actividad inmunoreguladora, método de aislamiento y usos.
BR112014001075A2 (pt) sonda, seu uso, método in vitro para associar uma sonda com um alvo e kit
BR112013018399A2 (pt) anticorpos anti-il1rap e seus usos para tratamento humano
BR112016014488A2 (pt) Meio para cultura celular
CO6761392A2 (es) Administración de proteínas a partir de microportadores de células madre
BRPI0417194A (pt) células-tronco
WO2008118392A3 (en) Synthetic cell platforms and methods of use thereof
BR112014007852A2 (pt) nucleosídeos, nucleotídeos e ácidos nucleicos modificados e usos dos mesmos
BR112014018524A2 (pt) derivados de pirimido [4,5-b]indol e métodos de utilização dos mesmos na expansão de células-tronco hematopoiéticas, composição farmacêutica e kits
BR0212469A (pt) Método para multiplicação de vìrus em cultura de célula
BG108492A (bg) Използване на въглероден окис за подобряване на резултатите при трансплантация на тъкани и органи и потискане на апоптозата
BR0207775A (pt) Lipossomos anfotéricos métodos para carregamento dos mesmos com ingredientes ativos e sua utilização
AR046123A1 (es) Aislamiento de celulas simil-celulas madre, uso de las mismas
AR094389A1 (es) USO DE INHIBIDORES DE iNOS PARA AUMENTAR EL RENDIMIENTO VÍRICO EN CULTIVOS
MX383334B (es) Celulas discogenicas aisladas, metodos de uso, y metodos de preparacion de las mismas a partir de tejido de mamifero.
RU2014146170A (ru) Способы лечения диабета и/или улучшения выживания панкреатических островков после трансплантации
BR112013005756A2 (pt) use of anti third party central memory t cells for anti-leukemia/lymphoma treatment
ES2626639T3 (es) Medicamento o composición dermatológica que contiene un extracto peptídico de aguacate destinado al tratamiento y a la prevención del prurito interno
ES2498926T3 (es) N-hidroxi-benzamidas para el tratamiento del cáncer
ATE544848T1 (de) Cokultur-lte (lymphoid tissue equivalent) für artifizielles immunsystem (ais)
CL2010000774A1 (es) Medio para el cultivo de celulas de mamiferos que comprende ademas de los nutrientes habituales de los medios de cultivo basales para cultivo de celulas de mamiferos, sobrenadante de la fraccion ii+iii del plasma humano segun el metodo de cohn; procedimiento de preparacion; y su uso.
AR039186A1 (es) Celulas madre indiferenciadas programables de origen monocitaro, su obtencion y uso
RU2012148391A (ru) СПОСОБЫ ИДЕНТИФИКАЦИИ, ВЫДЕЛЕНИЯ, ИСТОЩЕНИЯ И ОБОГАЩЕНИЯ ПОПУЛЯЦИЙ Tr1 КЛЕТОК, ПОПУЛЯЦИИ Tr1 КЛЕТОК, ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СПОСОБ МОНИТОРИНГА ЭФФЕКТА ТЕРАПИИ
Sheipouri et al. RETRACTED: Characterisation of the Kynurenine Pathway in Skin‐Derived Fibroblasts and Keratinocytes
AR125461A1 (es) Células presentadoras de antígeno recombinante